DE60027135T2 - Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen - Google Patents

Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen Download PDF

Info

Publication number
DE60027135T2
DE60027135T2 DE60027135T DE60027135T DE60027135T2 DE 60027135 T2 DE60027135 T2 DE 60027135T2 DE 60027135 T DE60027135 T DE 60027135T DE 60027135 T DE60027135 T DE 60027135T DE 60027135 T2 DE60027135 T2 DE 60027135T2
Authority
DE
Germany
Prior art keywords
gdf
cells
activity
protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027135T
Other languages
German (de)
English (en)
Other versions
DE60027135D1 (de
Inventor
Stavros Seattle TOPOUZIS
F. Jill Forest Hill WRIGHT
Tamara Columbia RATOVITSKI
Li-Fang Elkridge LIANG
L. James Bethesda BRADY
Debasish Gaithersburg SINHA
Linda Silver Spring YASWEN-CORKERY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetaMorphix Inc
Original Assignee
MetaMorphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60027135(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MetaMorphix Inc filed Critical MetaMorphix Inc
Application granted granted Critical
Publication of DE60027135D1 publication Critical patent/DE60027135D1/de
Publication of DE60027135T2 publication Critical patent/DE60027135T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DE60027135T 1999-01-21 2000-01-21 Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen Expired - Lifetime DE60027135T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11663999P 1999-01-21 1999-01-21
US116639P 1999-01-21
US13836399P 1999-06-10 1999-06-10
US138363P 1999-06-10
PCT/US2000/001552 WO2000043781A2 (en) 1999-01-21 2000-01-21 Growth differentiation factor inhibitors and uses therefor

Publications (2)

Publication Number Publication Date
DE60027135D1 DE60027135D1 (de) 2006-05-18
DE60027135T2 true DE60027135T2 (de) 2007-01-11

Family

ID=26814445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027135T Expired - Lifetime DE60027135T2 (de) 1999-01-21 2000-01-21 Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen

Country Status (12)

Country Link
EP (1) EP1147413B1 (enExample)
JP (1) JP2003517580A (enExample)
CN (1) CN100567322C (enExample)
AT (1) ATE322681T1 (enExample)
AU (2) AU772694B2 (enExample)
BR (1) BR0008188A (enExample)
CA (1) CA2359242C (enExample)
DE (1) DE60027135T2 (enExample)
HK (1) HK1041521B (enExample)
MX (1) MXPA01007366A (enExample)
NZ (1) NZ513642A (enExample)
WO (1) WO2000043781A2 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
ES2255059T3 (es) 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
EP1790726B1 (en) * 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
NZ530025A (en) 2001-06-05 2005-06-24 Inst Genetics Llc Methods for purifying highly anionic proteins
US20040248121A1 (en) * 2001-07-11 2004-12-09 Ravi Kambadur Bioassay for myostatin
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2003216345A1 (en) 2002-02-21 2003-09-09 Wyeth Follistatin domain containing proteins
AU2003217612A1 (en) 2002-02-21 2003-09-09 Wyeth GASP1: a follistatin domain containing protein
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
EA009056B1 (ru) * 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
WO2005094871A2 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
US7741284B2 (en) * 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
AU2005258286A1 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. GDF3 propeptides and related methods
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
CN101031294A (zh) * 2004-07-29 2007-09-05 先灵-普劳有限公司 Alk5抑制剂在调节或抑制导致动物瘦肉组织添加生长增强的肌肉生长抑制素活性中的用途
AU2006226878A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of GDF-8 modulating agents
CN101137906A (zh) * 2005-03-23 2008-03-05 惠氏公司 对gdf-8调节剂的免疫应答的检测
US8017576B2 (en) 2005-05-10 2011-09-13 The University Of Chicago Methods and compositions to treat mucositis
EP3327033A1 (en) 2005-08-19 2018-05-30 Wyeth LLC Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
UA116871C2 (uk) 2006-12-18 2018-05-25 Акселерон Фарма Інк. СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
CA2997971A1 (en) 2008-11-26 2010-06-03 Amgen Inc. Variants of activin iib receptor polypeptides and uses thereof
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2844123T3 (es) 2009-08-13 2021-07-21 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
US20130065820A1 (en) * 2009-10-01 2013-03-14 Covita Limited Synthetic myostatin peptide antagonists
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
CN107837390A (zh) 2011-10-17 2018-03-27 阿塞勒隆制药公司 用于治疗无效性红细胞生成的方法和组合物
AU2012364736A1 (en) 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
WO2014039189A1 (en) 2012-08-01 2014-03-13 Mcnally Elizabeth Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
CN104837832B (zh) 2012-10-05 2019-04-26 里格尔药品股份有限公司 Gdf-8抑制剂
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
MX2015009901A (es) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3808778A1 (en) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
CN106795224B (zh) 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016081364A1 (en) 2014-11-21 2016-05-26 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as tgf-beta inhibitors
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
CN107531666A (zh) 2015-02-20 2018-01-02 里格尔药品股份有限公司 Gdf‑8抑制剂
BR112017017135A2 (pt) 2015-03-02 2018-04-03 Rigel Pharmaceuticals, Inc. inibidores de tgf-beta
US11021468B2 (en) 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MA53400A (fr) 2015-04-06 2021-08-04 Acceleron Pharma Inc Hétéromultimères alk7: actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
SI3496739T1 (sl) 2016-07-15 2021-06-30 Acceleron Pharma Inc. Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
AU2017302282B2 (en) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
CN110198743B (zh) 2016-10-05 2023-07-18 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
AU2017338921A1 (en) 2016-10-05 2019-04-18 Acceleron Pharma Inc. ALK4:ActRIIB heteromultimers and uses thereof
EP3523328A4 (en) 2016-10-05 2020-04-01 Acceleron Pharma Inc. VARIANT ACTRIIB PROTEINS AND USES THEREOF
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP7715345B2 (ja) * 2019-06-26 2025-07-30 神戸天然物化学株式会社 ミオスタチン遺伝子のｍＲＮＡの産生を抑制する核酸医薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254678A (en) * 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
ES2201076T3 (es) * 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US5616466A (en) * 1993-11-05 1997-04-01 Cantor; Glenn H. Ribozyme-mediated inhibition of bovine leukemia virus
DK0776337T3 (da) * 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US6008434A (en) * 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US6124115A (en) * 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
WO1998024925A1 (en) * 1995-11-08 1998-06-11 Medical University Of South Carolina Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens
US5824519A (en) * 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
WO1998033887A1 (en) * 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
NO971997D0 (no) * 1997-04-29 1997-04-29 Kjetil Tasken Bruk av immunmodulerende midler
EP2045322B1 (en) * 1997-07-14 2015-07-01 Université de Liège Double-muscling in mammals
WO1999006559A1 (en) * 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
WO2000006716A1 (en) * 1998-07-28 2000-02-10 The Johns Hopkins University School Of Medicine Growth differentiation factor-11

Also Published As

Publication number Publication date
NZ513642A (en) 2004-02-27
WO2000043781A2 (en) 2000-07-27
MXPA01007366A (es) 2002-06-04
CA2359242A1 (en) 2000-07-27
ATE322681T1 (de) 2006-04-15
CN1355881A (zh) 2002-06-26
JP2003517580A (ja) 2003-05-27
EP1147413B1 (en) 2006-04-05
BR0008188A (pt) 2002-02-13
CA2359242C (en) 2009-12-08
AU2004203398A1 (en) 2004-08-19
HK1041521A1 (en) 2002-07-12
HK1041521B (en) 2006-11-17
WO2000043781A3 (en) 2001-02-01
AU772694B2 (en) 2004-05-06
AU2514000A (en) 2000-08-07
DE60027135D1 (de) 2006-05-18
EP1147413A2 (en) 2001-10-24
CN100567322C (zh) 2009-12-09

Similar Documents

Publication Publication Date Title
DE60027135T2 (de) Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
DE69727558T2 (de) Humanes CYR61, ein Signalmolekül der extrazellularen Matrix
DE69635738T2 (de) Neurturin und verwandte Wachstumsfaktoren
DE69819345T2 (de) Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
DE69430130T2 (de) Polypeptide von der semaphorin-genfamilie
DE69837845T3 (de) Osteoprotegerin bindende proteine und deren rezeptoren
DE69636752T2 (de) Menschlicher wachstumsfaktor 2, spezifisch für vaskuläre endothelzellen
DE69833014T2 (de) Menschliche toll homologen
DE69735364T2 (de) Modulatoren für die regenerierung von gewebe
DE69232986T2 (de) TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
DE69838061T2 (de) Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
DE69730607T2 (de) Fas ligand ähnliches protein, seine herstellung und verwendung
DE69727589T2 (de) Mutanten des KERATINOCYTEN-WACHSTUMSFAKTOR-2 (KGF-2 ODER FIBROBLASTENWACHSTUMSFAKTOR-12,FGF-12)
DE69733695T2 (de) Notch-liganden zur verwendung in der immuntherapie
DE69423007T3 (de) Dna codierend für einen menschlichen pankreaspolypeptid-rezeptor (y4) und seine verwendung
DE60107815T2 (de) Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
DE60028054T2 (de) Fibroblasten-wachstumsfaktor-19 (fgf-19) nukleinsäure und polypeptide und verfahren zu deren verwendung für behandlung von fettleibigkeit
DE69737418T2 (de) Protein mit der eigenschaft das altern zu unterdrücken
DE60128066T2 (de) Humanes cyr61
DE69837085T2 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
DE69934239T2 (de) Ly6h-gen
US7384634B2 (en) Connective tissue growth factor
DE69931345T2 (de) Gen, welches für neues transmembranprotein kodiert
DE60036548T2 (de) Neue kalium-kanäle und dafür kodierende gene
EP0805204B1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition